OOIR: Observatory of International Research

Papers

(The H4-Index of Journal for Immunotherapy of Cancer is 66. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2021-08-01 to 2025-08-01.)

Article	Citations
73 Characterization of tumor-infiltrating T-cell repertoire in human cancers	233
217 Cytotoxicity of nicotinamide enhanced natural killer cells GDA201 is based on metabolic modulation as demonstrated by artificial intelligence assisted analysis of NK cell transcriptome and metabol	190
38 Spatial immune profiling of human glioblastoma tissue reveals the presence of aggregated lymphoid niches in the tumor microenvironment	187
Commentary on oncolytic viruses: past, present, and future	178
Checkpoint inhibitor-expressing lentiviral vaccine suppresses tumor growth in preclinical cancer models	163
Response to "NLRC5germline variants and their potential role in eliciting an immune response in patients with cancer treated with immune checkpoint inhibitors" by Xiang-Yu Meng	152
Correction: Systematic preclinical evaluation of CD33-directed chimeric antigen receptor T cell immunotherapy for acute myeloid leukemia defines optimized construct design	147
Correction: Ultrasound combined with nanobubbles promotes systemic anticancer immunity and augments anti-PD1 efficacy	143
Correction: Treg-selective IL-2 starvation synergizes with CD40 activation to sustain durable responses in lymphoma models	136
Correction: PP4 inhibition sensitizes ovarian cancer to NK cell-mediated cytotoxicity via STAT1 activation and inflammatory signaling	135
Baseline and post-treatment biomarkers of resistance to anti-PD-1 therapy in acral and mucosal melanoma: an observational study	131
Correction: A systemically deliverable Vaccinia virus with increased capacity for intertumoral and intratumoral spread effectively treats pancreatic cancer	131
Arginase-2-specific cytotoxic T cells specifically recognize functional regulatory T cells	129
24 Nivolumab serum concentration in metastatic melanoma patients could be related to anti-tumor activity gene and outcome	126
Author response to comment on “Phase 2 study of neoadjuvant durvalumab plus docetaxel, oxaliplatin, and S-1 with surgery and adjuvant durvalumab plus S-1 for resectable locally advanced gastric cancer	124
Bempegaldesleukin plus nivolumab in first-line renal cell carcinoma: results from the PIVOT-02 study	123
Correction: Neoadjuvant nivolumab for patients with resectable HPV-positive and HPV-negative squamous cell carcinomas of the head and neck in the CheckMate 358 trial	116
Correction: Multi-institutional analysis of aneuploidy and outcomes to chemoradiation and durvalumab in stage III non-small cell lung cancer	115
HDL-cholesterol confers sensitivity of immunotherapy in nasopharyngeal carcinoma via remodeling tumor-associated macrophages towards the M1 phenotype	112
Immunotherapy reverses glioma-driven dysfunction of immune system homeostasis	112
Serum analytes as predictors of disease recurrence and the duration of invasive disease-free survival in patients with triple negative breast cancer enrolled in the OXEL trial treated with immunothera	111
T-cell tolerant fraction as a predictor of immune-related adverse events	110
Intratumoral microbiota predicts the response to neoadjuvant chemoimmunotherapy in triple-negative breast cancer	107
Inhibition of PNCK inflames tumor microenvironment and sensitizes head and neck squamous cell carcinoma to immune checkpoint inhibitors	105
Delivery of CD47 blocker SIRPα-Fc by CAR-T cells enhances antitumor efficacy	103

First-in-human phase I/Ib open-label dose-escalation study of GWN323 (anti-GITR) as a single agent and in combination with spartalizumab (anti-PD-1) in patients with advanced solid tumors and lymphoma	101
Single-cell analysis reveals clonally expanded tumor-associated CD57⁺CD8 T cells are enriched in the periphery of patients with metastatic urothelial cancer responding to PD-L1 blockade	100
Evaluation of immune checkpoint inhibitor efficacy for solid tumors withCD274(PD-L1 gene) amplification identified by comprehensive genomic profiling: retrospective study based on a nationwide	100
Comparison of tumor assessments using RECIST 1.1 and irRECIST, and association with overall survival	98
Oncolytic adenovirus serotype 35 mediated tumor growth suppression via efficient activation of antitumor immunity	96
Genomic and transcriptomic characterization of heterogeneous immune subgroups of microsatellite instability-high colorectal cancers	96
Visceral adiposity and systemic inflammation in the obesity paradox in patients with unresectable or metastatic melanoma undergoing immune checkpoint inhibitor therapy: a retrospective cohort study	91
TIPE2deletion improves the therapeutic potential of adoptively transferred NK cells	91
Cbl-b inhibitor NX-1607 activates MAPK/ERK signaling pathway and enhances T-cell activation	90
iRECIST and atypical patterns of response to immuno-oncology drugs	90
Pancreatic cancer cell-intrinsic transglutaminase-2 promotes T cell suppression through microtubule-dependent secretion of immunosuppressive cytokines	89
Patient-reported outcomes in adoptive cell-therapy trials: mind the gap	88
Novel PAP-targeted CAR-T therapy enhances antitumor efficacy through CoupledCAR approach	88
Correction: influenza vaccination and myocarditis among patients receiving immune checkpoint inhibitors	87
Novel phosphatidylserine-binding molecule enhances antitumor T-cell responses by targeting immunosuppressive exosomes in human tumor microenvironments	85
Correction: Dexmedetomidine induces immunogenic cancer cell death and sensitizes tumors to PD-1 blockade	84
Hybrid epithelial-mesenchymal status of lung cancer dictates metastatic success through differential interaction with NK cells	83
Lactylation-driven TNFR2 expression in regulatory T cells promotes the progression of malignant pleural effusion	80
Liquid biopsy approaches to capture tumor evolution and clinical outcomes during cancer immunotherapy	79
Phase I trial of KN046, a novel bispecific antibody targeting PD-L1 and CTLA-4 in patients with advanced solid tumors	79
Checkpoint blockade-induced CD8+ T cell differentiation in head and neck cancer responders	78
Human MAIT cells are devoid of alloreactive potential: prompting their use as universal cells for adoptive immune therapy	78
Transcriptional and functional analyses of neoantigen-specific CD4 T cells during a profound response to anti-PD-L1 in metastatic Merkel cell carcinoma	77
Serum albumin: a pharmacokinetic marker for optimizing treatment outcome of immune checkpoint blockade	76
Neoantigen architectures define immunogenicity and drive immune evasion of tumors with heterogenous neoantigen expression	75
Localization and density of tertiary lymphoid structures associate with molecular subtype and clinical outcome in colorectal cancer liver metastases	74
Tumor-associated macrophage-specific CD155 contributes to M2-phenotype transition, immunosuppression, and tumor progression in colorectal cancer	73
Is immunotherapy safe and effective in patients with VEXAS syndrome?	73
CD4+ T cell and M2 macrophage infiltration predict dedifferentiated liposarcoma patient outcomes	72
Challenges and opportunities in cancer immunotherapy: a Society for Immunotherapy of Cancer (SITC) strategic vision	72
Biomarkers for response to TIL therapy: a comprehensive review	72
B7-H3 CAR-T cell therapy combined with irradiation is effective in targeting bulk and radiation-resistant chordoma cancer cells	71
Macrophage-inherited exosome excise tumor immunosuppression to expedite immune-activated ferroptosis	71
GD2-targeting CAR-T cells enhanced by transgenic IL-15 expression are an effective and clinically feasible therapy for glioblastoma	70
EphA3-targeted chimeric antigen receptor T cells are effective in glioma and generate curative memory T cell responses	70
Targeting of GSDMD sensitizes HCC to anti-PD-1 by activating cGAS pathway and downregulating PD-L1 expression	70
Modulating lipid metabolism improves tumor immunotherapy	68
17 Predictive soluble biomarkers of immune response to checkpoint blockade in non-small cell lung cancer (NSCLC) patients	67
370 Time course of treatment-related adverse events (TRAEs) during dostarlimab therapy in the GARNET trial	67
389 Phase II of CD40 agonistic antibody sotigalimab (APX005M) in combination with nivolumab in subjects with metastatic melanoma with confirmed disease progression on anti-PD-1 therapy	66
77 Prevalence of secondary immunotherapeutic targets in the absence of established immune biomarkers in solid tumors	66